[[{“value”:”
HilleVax’s norovirus vaccine failed a Phase 2b study in infants, but it’s not the end of the road for the biotech. A business deal this year brought HilleVax a Phase 1-ready norovirus vaccine candidate designed to offer even broader protection.
The post A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants appeared first on MedCity News.
“}]]
